2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3036

The Association Between Behcet’s Disease, Myelodysplastic Syndrome and Trisomy 8
Abstract Number: 3037

Serum Anti-Lysozyme Is Associated with Disease Activity of Behcet’s Disease
Abstract Number: 3038

Serum CXCL8, 10 and 12 Are Increased in Patients with Behcet’s Disease and CXCL10 Levels Are Correlated with Number of Erythema Nodosum
Abstract Number: 3039

Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease
Abstract Number: 3040

Predictive Factors of Long-Term Clinical Outcome in Patients with Ocular Involvement Secondary to Behcet’s Syndrome
Abstract Number: 3041

Long Term Biological Therapy in Uveitis Refractory Due to Behçet’s Disease. Multicenter Study of 165 Patients.
Abstract Number: 3042

Tocilizumab in Refractory Uveitis Associated with Behçet’s Disease. Multicenter Study of 7 Patients.
Abstract Number: 3043

IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis
Abstract Number: 3044

Microparticles (MPs) Derived from Cell Plasma Membranes Are Increased in Behcet’s Syndrome (BS) and a Low Ratio of Tissue Factor Pathway Inhibitor Positive Mps to Tissue Factor Positive Mps (TFPI/TF) Is Associated with Thrombosis
Abstract Number: 3045

Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?
Abstract Number: 3046

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease
Abstract Number: 3047

Association Between Red Blood Cell Distribution Width and Disease Activity in Behcet’s Disease
Abstract Number: 3048

Work Disability over Time in Behcet’s Syndrome
Abstract Number: 3049

Cognitive Dysfunction in Chronic Progressive Neuro-Behçet’s Disease: Comparative Study of the Brainstem and Hippocampus Region Using Brain Magnetic Resonance Imaging
Abstract Number: 3050

Evaluation of Olfactory Function in Behcet’s Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].